Literature DB >> 17223106

Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector.

A Chtarto1, X Yang, O Bockstael, C Melas, D Blum, E Lehtonen, L Abeloos, J-M Jaspar, M Levivier, J Brotchi, T Velu, L Tenenbaum.   

Abstract

An autoregulated tetracycline-inducible recombinant adeno-associated viral vector (rAAV-pTet(bidi)ON) utilizing the rtTAM2 reverse tetracycline transactivator (rAAV-rtTAM2) was used to conditionally express the human GDNF cDNA. Doxycycline, a tetracycline analog, induced a time- and dose-dependent release of GDNF in vitro in human glioma cells infected with rAAV-rtTAM2 serotype 2 virus. Introducing the Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) downstream to the rtTAM2 coding sequence, resulted in a more rapid induction and a higher basal expression level. In vivo, 8 weeks after a single injection of the rAAV-rtTAM2-GDNF vector encapsidated into AAV serotype 1 capsids in the rat striatum, the GDNF protein level was 60 pg/mg tissue in doxycycline-treated animals whereas in untreated animals, it was undistinguishable from the endogenous level ( approximately 4 pg/mg tissue). However, a residual GDNF expression in the uninduced animals was evidenced by a sensitive immunohistochemical staining. As compared to rAAV1-rtTAM2-GDNF, the rAAV1-rtTAM2-WPRE-GDNF vector expressed a similar concentration of GDNF in the induced state (with doxycycline) but a basal level (without doxycycline) approximately 2.5-fold higher than the endogenous striatal level. As a proof for biological activity, for both vectors, downregulation of tyrosine hydroxylase was evidenced in dopaminergic terminals of doxycycline-treated but not untreated animals. In conclusion, the rAAV1-rtTAM2 vector which expressed biologically relevant doses of GDNF in the striatum in response to doxycycline with a basal level undistinguishable from the endogenous striatal level, as measured by quantitative ELISA assay, constitutes an interesting tool for local conditional transgenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17223106     DOI: 10.1016/j.expneurol.2006.11.014

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  16 in total

1.  Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.

Authors:  Luis Quintino; Giuseppe Manfré; Erika Elgstrand Wettergren; Angrit Namislo; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther       Date:  2013-07-24       Impact factor: 11.454

Review 2.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

3.  Rescue of Adeno-Associated Virus Production by shRNA Cotransfection.

Authors:  Maria C Guimaro; Sandra A Afione; Tsutomu Tanaka; John A Chiorini
Journal:  Hum Gene Ther       Date:  2020-04-28       Impact factor: 5.695

4.  A method to specifically activate the Klotho promoter by using zinc finger proteins constructed from modular building blocks and from naturally engineered Egr1 transcription factor backbone.

Authors:  Ci-Di Chen; Melissa A Rudy; Ella Zeldich; Carmela R Abraham
Journal:  FASEB J       Date:  2020-04-29       Impact factor: 5.191

5.  Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer.

Authors:  Lucia Vanrell; Marianna Di Scala; Laura Blanco; Itziar Otano; Irene Gil-Farina; Victor Baldim; Astrid Paneda; Pedro Berraondo; Stuart G Beattie; Abdelwahed Chtarto; Lilianne Tenenbaum; Jesús Prieto; Gloria Gonzalez-Aseguinolaza
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

6.  Deficiency in endothelin receptor B reduces proliferation of neuronal progenitors and increases apoptosis in postnatal rat cerebellum.

Authors:  Maria Vidovic; Ming-Ming Chen; Qun-Ying Lu; Katherine F Kalloniatis; Ben M Martin; Abel H Y Tan; Celina Lynch; G David H Croaker; Daniel T Cass; Zan-Min Song
Journal:  Cell Mol Neurobiol       Date:  2008-08-06       Impact factor: 5.046

Review 7.  Viral vectors and delivery strategies for CNS gene therapy.

Authors:  Steven J Gray; Kenton T Woodard; R Jude Samulski
Journal:  Ther Deliv       Date:  2010-10

8.  Impact of age at administration, lysosomal storage, and transgene regulatory elements on AAV2/8-mediated rat liver transduction.

Authors:  Gabriella Cotugno; Patrizia Annunziata; Maria Vittoria Barone; Marianthi Karali; Sandro Banfi; Alberto Auricchio
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240

9.  Gene regulation systems for gene therapy applications in the central nervous system.

Authors:  Jerusha Naidoo; Deborah Young
Journal:  Neurol Res Int       Date:  2012-01-05

10.  DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation.

Authors:  Eugénie Ansseau; Dalila Laoudj-Chenivesse; Aline Marcowycz; Alexandra Tassin; Céline Vanderplanck; Sébastien Sauvage; Marietta Barro; Isabelle Mahieu; Axelle Leroy; India Leclercq; Véronique Mainfroid; Denise Figlewicz; Vincent Mouly; Gillian Butler-Browne; Alexandra Belayew; Frédérique Coppée
Journal:  PLoS One       Date:  2009-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.